The FDA has given the green light to a new health evaluation-capable smartwatch from healthcare technology company Withings. The ScanWatch, in addition to tracking physical activity and identifying sleep disruption, has a built-in electrocardiogram sensor and blood oxygen monitor. It has, in fact, made history by becoming the first wearable to earn a concurrent clearance for SpO2 and ECG measurement.
The ScanWatch was refined with the guidance of sleep health experts and cardiologists, and validated through two clinical trials. Encased in stainless steel and featuring a sturdy sapphire glass watch face, the device has been fitted with an innovative crown dial that makes for easier navigation of functions and visibility of metrics. The ScanWatch is also waterproof, with a limit of 16-foot depth, and its impressive battery life can cover an entire month of regular use. As a part of the Withings product line, it seamlessly integrates with the company's paired Health Mate application, which generates insights and keeps users apprised of their health data trends.
Currently available in Australia and Europe, ScanWatch is set for a November launch in North America. German hospitals have had success in using the device for COVID-19 remote patient monitoring processes. Its ability to measure SpO2 levels, which helps providers identify severe COVID symptoms, is particularly useful in that regard.